Bernstein downgraded Biohaven (BHVN) to Market Perform from Outperform with a price target of $9, down from $34, following Tuesday’s announcement of the complete response letter for troriluzole in SCA. This is a painful downgrade, the firm notes, as Bernstein remains excited about the long-term value of the degrader platform, the original reason for its Outperform rating.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven downgraded to Neutral from Buy at BofA
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Midday Fly By: Broader market bought on dip after tech selloff
- Biohaven Ltd.: Strategic Initiatives and Financial Positioning Drive Buy Rating Amid FDA Challenges
- Biohaven downgraded to Market Perform from Outperform at William Blair